22
Jul
2021

Biogen’s Bumbling Defense, Delta on the Move, & PacBio’s Power Play

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

A Path Forward for More Biotech Workers
An Old Idea Whose Time Has Come
A Big Opportunity in Obesity
Regeneron Buys Checkmate, Bivalent Vaccine Progress, & a Fitting Acronym